



**LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
Pharmacy Affairs**

October 5th, 2020

TO: MHLA Clinics
 FROM: DHS Pharmacy Affairs
 RE: DHS MHLA Formulary Update

MY HEALTH LA FORMULARY

Due to recent distribution restrictions placed by Sanofi on MHLA formulary products, Lantus®, Flomax®, Rifadin® and Priftin®, access will be limited. **The temporary formulary amendments outlined below will go into effect October 6th, 2020.** We are working on a longer term solution. We appreciate your efforts to ensure MHLA participants' continuity of care and strongly encourage MHLA Clinics to proactively work with your 340B contract pharmacies as we navigate through these manufacturer-mandated 340B distribution restrictions.

UPDATE – Temporary Formulary Amendment (effective October 6th, 2020)

Drug Product	Comments
Lantus® Vial and Lantus® Solostar Pen	<p>Lantus® claims will temporarily <u>reject for contract 340B pharmacies</u> with the message “Contact the CCT at 855-444-7757 for guidance.”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none"> • <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options (i.e., Levemir®). • <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options (i.e., Levemir®).

This document contains confidential information intended for MHLA Program Healthcare Providers and Professionals only. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.

<p>Flomax®</p>	<p>Flomax® brand restriction removed. Flomax® claims will temporarily <u>reject for contract 340B pharmacies</u> with the message “Brand not covered. Use generic.”</p>
<p>Rifadin®</p>	<p>Rifadin® claims will temporarily <u>reject for contract 340B pharmacies</u> with the message “Brand not covered. Use generic.”</p>
<p>Priftin®</p>	<p>Priftin® claims will temporarily <u>reject for contract 340B pharmacies</u> with the message “Contact the CCT at 855-444-7757 for guidance.”</p> <p>If you are calling from a contract pharmacy servicing a MHLA participant from a MHLA clinic that:</p> <ul style="list-style-type: none"> • <u>Has an On-Site Pharmacy or Dispensary:</u> CCT will advise you to direct the MHLA participant to their MHLA Clinic on-site pharmacy and transfer prescription as appropriate. If the participant is unable to travel to their on-site clinic pharmacy or dispensary, please contact the prescriber for alternative formulary options (i.e., Rifampin). • <u>Does NOT have an On-site Pharmacy or Dispensary:</u> CCT will advise you to contact the prescriber for alternative formulary options (i.e., Rifampin).

NOTE: Sanofi’s distribution restrictions **do NOT apply to On-Site Pharmacies and Dispensaries**. Lantus®, Flomax®, Rifadin® and Priftin® will continue to process according to prior formulary restrictions at these locations.